Order LIOMNY™ online
If you run into issues, just give us a call at 800-810-7790.
LIOMNY™ (T3) For Hypothyroidism
Engineered for Consistency, Built for Reliability
- Available in 5mcg, 25mcg, and 50 mcg tablets
- Made in USA by Sigmapharm Laboratories
- Gluten-free tablets
Precision Matters with Your Thyroid Medication
When it comes to thyroid medications, every microgram counts. Liothyronine sodium, the active ingredient in LIOMNY™, has a narrow therapeutic window.
- Too much can cause serious side effects.
- Too little can leave symptoms untreated.
That’s why precision and consistency in every dose are critical.
Patients who find themselves frustrated being switched between different manufacturers of generic liothyronine sodium now have a named version they can easily identify. Sigmapharm’s liothyronine sodium tablets, USP, is now available under the name LIOMNY™ for easier accessibility.
How LIOMNY™ Maintains Consistency
Tight Manufacturing Standards
LIOMNY™ is manufactured with tight assay and uniformity specifications to demonstrate potency and consistency.
- Assay: measures the amount of active ingredient present in a pharmaceutical dosage form.
- Uniformity: describes the homogeneity of active ingredient dispersed evenly in a drug product.
The United States Pharmacopeia (USP) and National Formulary (NF) allow for an assay acceptance range of 90.0% – 110.0% for liothyronine sodium in each batch. LIOMNY™ goes further, tightening its range to 95.0% – 105.0%. In addition to its assay, the compendial uniformity acceptance range for LIOMNY™ is tightened by 10.0% compared to the content uniformity range deviation acceptance criteria of the USP/NF.
USP/NF Assay Acceptance Criteria:
90.0% - 110.0%
90.0% - 110.0%
LIOMNY™ Assay Acceptance Criteria:
95.0% - 105.0%
95.0% - 105.0%
Compendial Uniformity Acceptance Range Tightened by 10.0%
What This Means for You
Tight assay and uniformity manufacturing specifications in a drug may lead to more accurate reflections of its true dosage strength displayed on the bottle/label. A higher rate of such consistent dosages per tablet may reduce the risk of variability in treatment efficacy.
Who Can Benefit from LIOMNY™?
LIOMNY™ (liothyronine sodium tablets, USP) is a synthetic T3 hormone. While most people with hypothyroidism respond well to T4 (thyroxine) therapy, some continue to experience symptoms even when their T4 levels appear normal.
In such cases, the body doesn’t produce enough active T3, the hormone that actually powers metabolism and energy.
LIOMNY™ May Help If You:
- Still feel unwell on T4-only therapy
- Have normal T4 levels but low T3 levels
- Have known issues with thyroid hormone conversion
Choose LIOMNY™
A uniform and consistent T3 medication
How to Order LIOMNY™
We will verify your prescription
We can contact your doctor for the prescription.
We will ship it to your home
We ship through First Class Mail to all 50 states.
Have questions about LIOMNY™?
Talk with a pharmacist today. Call us for a free pharmacy consult.
800-810-7790
Stable. Uniform. Consistent. That’s LIOMNY™
Liothyronine (T3) is a powerful thyroid hormone with a narrow therapeutic index – meaning even small changes in dose can make a big difference in how you feel. That’s why consistency matters.
If you find yourself being switched between different generic liothyronine sodium products, LIOMNY™ can be easy to identify and order.
Attributes of LIOMNY™
- Strict assay criteria:
LIOMNY™ is manufactured to stay within 95.0% – 105.0% of the labeled dose, compared to the USP/NF assay acceptance criteria of 90.0% – 110.0%. - Tight uniformity acceptance range:
LIOMNY™ tightens the compendial uniformity acceptance range by 10.0% compared to the content uniformity range deviation acceptance criteria of the USP/NF.
With LIOMNY™ you’re choosing a stable, uniform, and consistent product.
Frequently Asked Questions
IMPORTANT SAFETY INFORMATION FOR LIOMNY™ (liothyronine sodium tablets, USP)
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
See full prescribing information for complete boxed warning.
- Thyroid hormones, including LIOMNY™ should not be used for the treatment of obesity or for weight loss.
- Doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity.
INDICATIONS & USAGE
LIOMNY™ is an L-triiodothyronine (T3) indicated for:
Hypothyroidism
As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism
Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression
As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer
Thyroid Suppression Test
As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy
Limitations of Use:
- Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients.
- Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
Dosing and Administration
Administer LIOMNY™ orally once daily and individual dosage according to patient response and laboratory findings. (See full prescribing information for recommended dosage for hypothyroidism.) TSH suppression in well-differentiated thyroid cancer and for thyroid suppression test. When switching a patient to LIOMNY™, discontinue levothyroxine therapy and initiate LIOMNY™ at a low dosage. Gradually increase the dose according to the patient’s response. Adequacy of therapy determined with periodic monitoring of TSH and T3 levels as well as clinical status.
Dosage Forms and Strengths
Tablets: 5 mcg, 25 mcg, 50 mcg
CONTRAINDICATIONS
LIOMNY™ is contraindicated in patients with uncorrected adrenal insufficiency.
Warnings and Precautions
Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate LIOMNY™ at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation.
Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma.
Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of LIOMNY™ treatment.
Prevention of hypothyroidism or incomplete treatment of hypothyroidism: Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism.
Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy.
Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone resorption and decrease bone mineral density. Give the lowest effective dose.
Adverse Reactions
Most common adverse reactions for LIOMNY™ are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash.
To report SUSPECTED ADVERSE REACTIONS, contact Sigmapharm Laboratories LLC,
Pharmacovigilance at 1-855-332-0731 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Drug Interactions
See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to LIOMNY™.
Use in Specific Patient Populations
Pregnancy may require the use of higher doses of thyroid hormone.
This prescribing information is not comprehensive, please see the full prescribing information for LIOMNY™.